Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.
Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Raj K. Puri(Integrated BioTherapeutics (United States)), Koji Kawakami(Kyoto University), Diva R. Salomão(Mayo Clinic in Arizona), Danielle Alejandro(Mayo Clinic), Stephen G. Voss, Jan L. Kasperbauer(Mayo Clinic), Richard A. Maki(Neurocrine Biosciences (United States)), Lieping Chen(Yale Cancer Center)
PubMed
January 1, 2002
Cited by 26
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
|Nature Biotechnology|2006|2.2k
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
|Journal of Clinical Investigation|2015|1.4k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k